IBR733 cell therapy for acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 74 years old.
- You must have acute myeloid leukemia (AML) that has relapsed or is refractory (not responding to standard treatments).
- You must be willing to use effective birth control for 6 months after the treatment if you or your partner can have children.
- You must not have had a stem cell or organ transplant.
- You must not have had certain other cancer treatments (like CAR-T therapy) before.
- You must not have serious heart, liver, kidney, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
This trial tests an experimental treatment called BG1805 for children with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. BG1805 is a type of cell therapy (like CAR-T) that targets the CLL-1 marker on leukemia cells, potentially helping the body fight the cancer.
This trial tests a new type of immune cell therapy that uses your own cells, modified to attack leukemia cells in multiple ways. It aims to find a safe and effective dose for people with acute myeloid leukemia who have not responded to other treatments.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.